Literature DB >> 16537559

Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation.

Tamara Gastaldi1, Paolo Bonvini, Francesca Sartori, Agnese Marrone, Achille Iolascon, Angelo Rosolen.   

Abstract

Plakoglobin (gamma-catenin) and beta-catenin are pivotal components of cell-cell adherent junctions that link cadherin receptors to the actin cytoskeleton. Whereas beta-catenin overexpression induces cell proliferation and tumor formation, plakoglobin induces tumor suppressor activity. We investigated the expression of plakoglobin in alveolar (ARMS) and embryonal (ERMS) rhabdomyosarcoma (RMS) cell lines and tumors, and found that plakoglobin is present both in the cytoplasm and in the nucleus of ERMS cells, whereas it is absent or detectable at extremely low levels in ARMS. As gene silencing can be mediated by methylation and/or deacetylation of promoter regions, we assessed the effects of the DNA demethylating agent 5-Aza-2'-deoxycytidine (5AzadC) and of the histone deacetylase inhibitor Trichostatin A (TSA), and obtained restoration of plakoglobin expression in ARMS cells cultivated in the presence of 5AzadC and TSA. By methylation-specific PCR, ARMS cells were shown to contain methylated CpG dinucleotides in CpG islands located around the transcriptional start site of one or both alleles, whereas ERMS cells did not. Furthermore, we demonstrated that promoter regions (P1-P3) of plakoglobin gene were associated with hypoacetylated H4 histone in ARMS cells RH4, suggesting that aberrant DNA methylation of the 5' CpG island and histone deacetylation play key roles in silencing the plakoglobin gene. These results demonstrate that plakoglobin is differentially expressed in ARMS and ERMS and that its expression depends on the methylation and acetylation status of the gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537559     DOI: 10.1093/carcin/bgl008

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  γ-Catenin is an independent prognostic marker in early stage colorectal cancer.

Authors:  Jutta Maria Nagel; Lydia Kriegl; David Horst; Jutta Engel; Shiva Gautam; Christos S Mantzoros; Thomas Kirchner; Burkhard Göke; Frank Thomas Kolligs
Journal:  Int J Colorectal Dis       Date:  2010-08-25       Impact factor: 2.571

3.  Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas.

Authors:  Sarah E Mahoney; Zizhen Yao; C Chip Keyes; Stephen J Tapscott; Scott J Diede
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

Review 4.  Pediatric Rhabdomyosarcoma.

Authors:  Jack F Shern; Marielle E Yohe; Javed Khan
Journal:  Crit Rev Oncog       Date:  2015

Review 5.  DNA methylation dynamics in muscle development and disease.

Authors:  Elvira Carrió; Mònica Suelves
Journal:  Front Aging Neurosci       Date:  2015-03-05       Impact factor: 5.750

6.  Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.

Authors:  Francesca Megiorni; Samantha Cialfi; Heather P McDowell; Armando Felsani; Simona Camero; Alessandro Guffanti; Barry Pizer; Anna Clerico; Alessandra De Grazia; Antonio Pizzuti; Anna Moles; Carlo Dominici
Journal:  BMC Cancer       Date:  2014-11-25       Impact factor: 4.430

7.  Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.

Authors:  L Tombolan; E Poli; P Martini; A Zin; C Millino; B Pacchioni; B Celegato; G Bisogno; C Romualdi; A Rosolen; G Lanfranchi
Journal:  BMC Cancer       Date:  2016-11-14       Impact factor: 4.430

8.  Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin.

Authors:  L Lam; Z Aktary; M Bishay; C Werkman; C-Y Kuo; M Heacock; N Srivastava; J R Mackey; M Pasdar
Journal:  Oncogenesis       Date:  2012-03-19       Impact factor: 7.485

9.  MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.

Authors:  Lucia Tombolan; Matteo Zampini; Silvia Casara; Elena Boldrin; Angelica Zin; Gianni Bisogno; Angelo Rosolen; Cristiano De Pittà; Gerolamo Lanfranchi
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

10.  Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.

Authors:  E J Gang; Y-T Hsieh; J Pham; Y Zhao; C Nguyen; S Huantes; E Park; K Naing; L Klemm; S Swaminathan; E M Conway; L M Pelus; J Crispino; C G Mullighan; M McMillan; M Müschen; M Kahn; Y-M Kim
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.